No Impact With Mifepristone in Patients With Meningioma
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of failure-free or overall survival, according to a study published online ahead of print in the Journal of Clinical Oncology.1
In a multicenter, prospective, randomized, placebo-controlled phase 3 trial, researchers led by Yongli Ji, MD, of the University of Vermont Cancer Center in Burlington, VT, randomly assigned 164 patients to either mifepristone or placebo for 2 years or until disease progression.
Patients who were stable or had responded to therapy after 2 years had the option to continue therapy, and time to treatment failure and overall survival rate were measured.
RELATED: Proton Therapy Well-Tolerated for Low-Grade Gliomas
The researchers found that 24 patients were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. In addition, 28 patients in the placebo group were able to complete the 2-year study.
They observed no statistical difference between the 2 arms in terms of failure-free or overall survival, and concluded that long-term administration of mifepristone had no significant impact on this patient population.
- Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 [published online ahead of print November 2, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.6490.